Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchjmjd6gastric cancerpd-l1oncology

Study links JMJD6 overexpression to immune evasion in gastric cancer

Japanese researchers describe a BRD4-IRF1-PD-L1 axis driving malignancy, reported in Gan to Kagaku Ryoho.

PR
By Priya Raman · Science Reporter
Aug 31 20:00 ETSource: Gan to kagaku ryoho. Cancer & chemotherapy

The wire

  1. 01Researchers report JMJD6 overexpression promotes immune evasion via a BRD4-IRF1-PD-L1 axis.
  2. 02The pathway could inform gastric cancer immunotherapy targets.
  3. 03Findings are preclinical; therapeutic translation remains unproven.

From the source

[Overexpression of JMJD6 Drives Immune Evasion via the BRD4-IRF1-PD-L1 Axis and Promotes Malignancy in Gastric Cancer]

Gan to kagaku ryoho. Cancer & chemotherapy · 2026 Sep · Ishida R, Komatsu S, Arakawa H et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42750620/